Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 12, 2017 16:01 ET | Source: Adamas Pharmaceuticals, Inc.

Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology

--Placebo-Controlled Phase 3 Trial Demonstrated that ADS-5102 Significantly Reduced Both Dyskinesia and OFF Time at Six Months in Parkinson’s Disease Patients with Levodopa-induced Dyskinesia -- --...